Ibrahim Aldoss, MD, associate professor, City of Hope, explores recent findings on ponatinib as a first-line treatment for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric ...

Highlights in acute lymphoblastic leukemia (ALL), presented at the American Society of Hematology (ASH) 2024 Annual Meeting and Exposition, include studies on pediatric and adult disease ...

Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. It affects certain cells in the immune system, called B cells and T cells. ALL usually affects B cells in children.

An international clinical trial shows an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects.

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

The treatment of leukemia among children could be made more precise with fewer side effects with the help of more accurate ...

Phase-specific costs of care in diffuse large B-cell lymphoma in Ontario, Canada. Efficacy and safety of intramuscular (IM) recombinant Erwinia asparaginase in acute lymphoblastic leukemia (ALL) or ...